Ultra-high survival rate and disease control rate, proton heavy ion precision radiotherapy can effectively improve the prognosis of patients with osteosarcoma!

Osteosarcoma is the most common primary bone malignancy, mostly occurring in adolescents or childre.

As the world's most advanced radiotherapy method, proton-heavy ion therapy can achieve precise radiotherapy for osteosarcoma, while ensuring the therapeutic effect of osteosarcoma, and improving the quality of life of patient.

Proton heavy ion therapy for osteosarcoma has a survival rate of up to 75%

In 2021, a study published in the authoritative medical journal "RADIOTHERAPY AND ONCOLOGY" confirmed that proton heavy ions can significantly improve the prognosis of osteosarcoma, with a survival rate of 75%!

▲ Source: reference source [1]

The study included patients with primary, metastatic, or recurrent, inoperable osteosarcoma diagnosed between August 2011 and September 2018 and treated with 54 Gy of proton therapy and 18 Gy of heavy ion therap.

The results showed that after one year of treatment, the local control rate (LPFS) was 73%, the progression-free survival (PFS) rate was 60%, and the overall survival rate was 75%; after two years of treatment, the local control rate was 55%, The progression-free survival rate was 45%, and the overall survival rate was 68%; and the researchers did not find serious toxic side effect.

▲ Source: reference source [1]

Proton heavy ion treatment of osteosarcoma has a control rate of 92%

In 2017, a clinical study conducted by Japanese researchers and published in "Int J Radiat Oncol Biol Phys" analyzed the effect of proton-heavy ion therapy on bone and soft tissue tumor.

The study included 91 patients with bone and soft tissue sarcomas, including chordoma, chondrosarcoma, and osteosarcoma, diagnosed between May 2005 and December 2014, of whom 82 were primary and 9 were recurren.

The results of the study showed that the 3-year overall survival (OS), progression-free survival (PFS) and local control rates of proton heavy ion therapy for bone and soft tissue tumors were 83%, 72% and 92%, respectively; toxic side effect.

▲ Source: reference source [2]

Bone and soft tissue tumors are collectively referred to as bone tumors and soft tissue tumors, including osteosarcoma, Ewing sarcoma, chondrosarcoma, chordoma and other tumor.

In addition, there are several studies to confirm the effect of proton heavy ions in the treatment of osteosarcoma:

Reference source:

[1] The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma - Radiotherapy and Oncology

Demizu Y, Jin D, Sulaiman NS, Nagano F, Terashima K, Tokumaru S, Akagi T, Fujii O, Daimon T, Sasaki R, Fuwa N, Okimoto .

[3] Proton-Based Radiotherapy for Unresectable or Incompletely Resected Osteosarcoma

Osteoarthritis にする Heavy Ion Radiation Therapy について｜Imai Reiko-QST Hospital (Former Radiology Institute Hospital)｜Heavy Ion Radiation Therapy (がん Therapy)

END -

: .